{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:47Z","timestamp":1792788467643,"version":"4.5.0"},"reference-count":39,"publisher":"BMJ","issue":"1","funder":[{"name":"Immunicum AB"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40425-017-0255-0","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T14:14:30Z","timestamp":1497881670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma"],"prefix":"10.1136","volume":"5","author":[{"given":"Anna","family":"Laurell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"L\u00f6nnemark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Brekkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Magnusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Carin","family":"Wallgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Kiessling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1050-7908","authenticated-orcid":false,"given":"Alex","family":"Karlsson-Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,6,20]]},"reference":[{"issue":"13","key":"255_CR1","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","volume":"33","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430\u20137.","journal-title":"J Clin Oncol"},{"issue":"7528","key":"255_CR2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","volume":"515","author":"MM Gubin","year":"2014","unstructured":"Gubin MM, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577\u201381.","journal-title":"Nature"},{"issue":"6230","key":"255_CR3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69\u201374.","journal-title":"Science"},{"issue":"6236","key":"255_CR4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno BM, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348(6236):803\u20138.","journal-title":"Science"},{"key":"255_CR5","doi-asserted-by":"crossref","unstructured":"Zhang X, et al. Personalized cancer vaccines: Targeting the cancer mutanome. Vaccine. 2017;35(7):1094-1100.","DOI":"10.1016\/j.vaccine.2016.05.073"},{"issue":"3","key":"255_CR6","first-page":"1165","volume":"118","author":"C Liu","year":"2008","unstructured":"Liu C, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008;118(3):1165\u201375.","journal-title":"J Clin Invest"},{"issue":"6","key":"255_CR7","doi-asserted-by":"crossref","first-page":"e11144","DOI":"10.1371\/journal.pone.0011144","volume":"5","author":"AW Yewdall","year":"2010","unstructured":"Yewdall AW, et al. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS One. 2010;5(6):e11144.","journal-title":"PLoS One"},{"issue":"11","key":"255_CR8","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1128\/JVI.02267-10","volume":"85","author":"MF Pascutti","year":"2011","unstructured":"Pascutti MF, et al. Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells. J Virol. 2011;85(11):5532\u201345.","journal-title":"J Virol"},{"issue":"3","key":"255_CR9","doi-asserted-by":"crossref","first-page":"e1002572","DOI":"10.1371\/journal.ppat.1002572","volume":"8","author":"A Smed-Sorensen","year":"2012","unstructured":"Smed-Sorensen A, et al. Influenza a virus infection of human primary dendritic cells impairs their ability to cross-present antigen to CD8 T cells. PLoS Pathog. 2012;8(3):e1002572.","journal-title":"PLoS Pathog"},{"issue":"3","key":"255_CR10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/ni.2514","volume":"14","author":"IK Pang","year":"2013","unstructured":"Pang IK, Ichinohe T, Iwasaki A. IL-1R signaling in dendritic cells replaces pattern-recognition receptors in promoting CD8(+) T cell responses to influenza a virus. Nat Immunol. 2013;14(3):246\u201353.","journal-title":"Nat Immunol"},{"issue":"5","key":"255_CR11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nri3665","volume":"14","author":"A Iwasaki","year":"2014","unstructured":"Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol. 2014;14(5):315\u201328.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"255_CR12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/ni1223","volume":"6","author":"G Napolitani","year":"2005","unstructured":"Napolitani G, et al. Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol. 2005;6(8):769\u201376.","journal-title":"Nat Immunol"},{"issue":"14","key":"255_CR13","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1158\/0008-5472.CAN-07-6494","volume":"68","author":"K Gustafsson","year":"2008","unstructured":"Gustafsson K, et al. Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine. Cancer Res. 2008;68(14):5965\u201371.","journal-title":"Cancer Res"},{"issue":"3","key":"255_CR14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-3083.2005.01663.x","volume":"62","author":"AC Wallgren","year":"2005","unstructured":"Wallgren AC, et al. Direct allorecognition promotes activation of bystander dendritic cells and licenses them for Th1 priming: a functional link between direct and indirect allosensitization. Scand J Immunol. 2005;62(3):234\u201342.","journal-title":"Scand J Immunol"},{"key":"255_CR15","volume-title":"Improvement of adoptive T-cell therapy for Cancer, in Faculty of Medicine","author":"C Jin","year":"2016","unstructured":"Jin C. Improvement of adoptive T-cell therapy for Cancer, in Faculty of Medicine. Uppsala: Uppsala University: Acta Universitatis Upsaliensis; 2016."},{"issue":"8","key":"255_CR16","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/bjc.2011.368","volume":"105","author":"K Hotta","year":"2011","unstructured":"Hotta K, et al. Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. Br J Cancer. 2011;105(8):1191\u20136.","journal-title":"Br J Cancer"},{"issue":"2","key":"255_CR17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"19","key":"255_CR18","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"1","key":"255_CR19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm1517","volume":"13","author":"AT Parsa","year":"2007","unstructured":"Parsa AT, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84\u20138.","journal-title":"Nat Med"},{"issue":"13","key":"255_CR20","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1158\/1078-0432.CCR-13-2797","volume":"20","author":"M Atefi","year":"2014","unstructured":"Atefi M, et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014;20(13):3446\u201357.","journal-title":"Clin Cancer Res"},{"issue":"7528","key":"255_CR21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"issue":"4","key":"255_CR22","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"48","key":"255_CR23","doi-asserted-by":"crossref","first-page":"E7769","DOI":"10.1073\/pnas.1607836113","volume":"113","author":"L Danilova","year":"2016","unstructured":"Danilova L, et al. Association of PD-1\/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci U S A. 2016;113(48):E7769\u201377.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"255_CR24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clgc.2013.09.008","volume":"12","author":"C Chevreau","year":"2014","unstructured":"Chevreau C, et al. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. Clin Genitourin Cancer. 2014;12(1):50\u20134.","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"255_CR25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2008.18.0000","volume":"27","author":"AR Golshayan","year":"2009","unstructured":"Golshayan AR, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. 2009;27(2):235\u201341.","journal-title":"J Clin Oncol"},{"issue":"6","key":"255_CR26","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-08-4709","volume":"69","author":"J Ozao-Choy","year":"2009","unstructured":"Ozao-Choy J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69(6):2514\u201322.","journal-title":"Cancer Res"},{"issue":"6","key":"255_CR27","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","volume":"15","author":"JS Ko","year":"2009","unstructured":"Ko JS, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15(6):2148\u201357.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"255_CR28","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/ijc.25863","volume":"129","author":"A Bose","year":"2011","unstructured":"Bose A, et al. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer. 2011;129(9):2158\u201370.","journal-title":"Int J Cancer"},{"issue":"2","key":"255_CR29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.juro.2010.09.086","volume":"185","author":"JA Karam","year":"2011","unstructured":"Karam JA, et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011;185(2):439\u201344.","journal-title":"J Urol"},{"issue":"8","key":"255_CR30","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/bjc.2014.25","volume":"110","author":"JJ Ko","year":"2014","unstructured":"Ko JJ, et al. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer. 2014;110(8):1917\u201322.","journal-title":"Br J Cancer"},{"issue":"34","key":"255_CR31","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794\u20139.","journal-title":"J Clin Oncol"},{"key":"255_CR32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-015-0055-3","volume":"3","author":"A Amin","year":"2015","unstructured":"Amin A, et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J Immunother Cancer. 2015;3:14.","journal-title":"J Immunother Cancer"},{"issue":"22","key":"255_CR33","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","volume":"22","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, et al. Immunomodulatory activity of Nivolumab in metastatic renal cell carcinoma. Clin Cancer Res. 2016;22(22):5461\u201371.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"255_CR34","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.eururo.2011.05.028","volume":"60","author":"T Powles","year":"2011","unstructured":"Powles T, et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur Urol. 2011;60(3):448\u201354.","journal-title":"Eur Urol"},{"issue":"4","key":"255_CR35","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298\u2013306.","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"255_CR36","first-page":"5132","volume":"61","author":"O Nakano","year":"2001","unstructured":"Nakano O, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001;61(13):5132\u20136.","journal-title":"Cancer Res"},{"issue":"15","key":"255_CR37","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1158\/1078-0432.CCR-12-3847","volume":"19","author":"R Remark","year":"2013","unstructured":"Remark R, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res. 2013;19(15):4079\u201391.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"255_CR38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer RJ, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289\u201396.","journal-title":"J Clin Oncol"},{"issue":"2","key":"255_CR39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","volume":"14","author":"DYC Heng","year":"2013","unstructured":"Heng DYC, et al. External validation and comparison with other models of the International metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141\u20138.","journal-title":"Lancet Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-017-0255-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:42:41Z","timestamp":1601041361000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-017-0255-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,20]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["255"],"URL":"https:\/\/doi.org\/10.1186\/s40425-017-0255-0","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,20]]},"article-number":"52"}}